NCT00826891Unknown2 期
Phase II Study of Cisplatin Combined With Topotecan in Advanced (Stage IVB) Recurrent or Persistent Cervical Cancer
Chinese Anti-Cancer Association0 个研究点目标入组 40 人开始时间: 2009年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 40
- 主要终点
- Response rate (CR + PR) (RECIST)
研究概览
简要总结
This is a single arm, open-label study in women from China who have Advanced (stage IVB) Recurrent or Persistent cervical cancer to ⑴assess the response rate (i.e., CR + PR) of Cisplatin combined with Topotecan in treatment of advanced (stage IVB) recurrent or persistent Cervical cancer; ⑵assess the toxicities of CT regimen in treatment of cervical cancer. Prior to treatment, written informed consent should be obtained from all patients. Eligible patients will be assigned to CT regimen. The CT regimen is topotecan 0.75 mg/m2 IV during 30minutes days 1, 2, and 3; followed by cisplatin 50 mg/m2 IV on day1, repeated every 21 days. The study will consist of two phases: the safety run-in phase and study phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •women with advanced recurrent or persistent carcinoma of the uterine cervical who were unsuitable candidates for curative treatment with surgery and/or radiotherapy.
- •Histologic types included squamous, adenosquamous, and adenocarcinoma of the cervia.
- •Patients must be at least 18 years old.
- •Measurable and/or evaluable disease parameters will be documented and recorded using clinical evaluation (and using CT for pathologic nodes when present).
- •Life expectation greater than 3 months.
- •Patients must have adequate organ function.
- •Patients without history of sensitivity to camptothecin or platinum.
- •Patients who are non-child-bearing potential, or consistent and correct use of methods of birth control from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of observational medication.
- •performance status 0 to 2; to have recovered from the effects of recent surgery, chemoradiotherapy, or radiotherapy; and to be free of clinically significant infection.
- •Written informed consent
排除标准
- •Patients with uncontrolled infections.
- •Patients with concurrent severe medical problems unrelated to the malignancy which would expose the patient to extreme risk.
- •Patients who received another investigational drug within 30 days prior to study entry.
- •Patients who are receiving concurrent other chemotherapy, hormonal, immunotherapy or radiotherapy. Radiotherapy for palliation of related bone metastases is permitted.
- •Patients with a history of allergic reactions to compounds chemically related to topotecan or platinum.
- •Patients who are pregnant or lactating
- •Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin.
结局指标
主要结局
Response rate (CR + PR) (RECIST)
时间窗: 4~6 weeks after the end of treatment
次要结局
- Toxicity [NCI CTCAE (Version 3.0)](4~6 weeks after the end of treatment)
研究者
相似试验
Unknown
1 期
Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma CervixMetastatic Carcinoma to the Uterine CervixRecurrent Carcinoma CervixCervix Carcinoma RecurrentNCT02492503All India Institute of Medical Sciences, New Delhi40
已完成
2 期
Phase II trial of Cisplatin and Irinotecan treatment as palliative-intended chemotherapy for previously untreated advanced thymic carcinomathymic carcinomaJPRN-UMIN000012175Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital
已完成
2 期
Irinotecan Study For Cervical CancerUterine Cervical NeoplasmsNCT00136955Pfizer41
已完成
2 期
A phase II study of cisplatin with TS-1 for patients with cancer of primary unknowJPRN-C000000271Department of Medical Oncology, Kinki University School of Medicine45
已完成
2 期
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical CancerCervical CancerNCT00548418Washington University School of Medicine27